Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
Plant-based molecular farming platform for bio-identical collagen production
LeafyColl is a biotech developing a molecular farming platform for the scalable, plant-based production of bio-identical human collagen and other specialty proteins. The system uses engineered plants as programmable bio-factories to produce high-purity collagen for applications spanning regenerative medicine, wound…
Asymmetric biomaterial skin substitutes for acute and chronic wounds
Janus Biosciences is a biotech developing novel biomaterial skin substitutes for the treatment of acute and chronic wounds. The platform is based on asymmetric Janus material architectures, in which opposing faces of the scaffold present distinct physicochemical properties to simultaneously support wound bed healing…
Programmable RNA for scalable cell engineering and biomanufacturing
Plurify is a biotechnology company developing PluRNA, a programmable RNA platform for sustained protein expression without genome integration. Its technology is designed to engineer cells through controllable RNA-based programmes, with applications in stem-cell therapy manufacturing, cell purification, biologics…
Graphene nanocomposites and biomaterials for regenerative medicine research
NanoRegMed is a London biotechnology company developing graphene-based polymers and nanocomposites for regenerative medicine and industrial applications. Its Hastalex and BioHastalex materials have tunable properties for potential tissue repair and implant applications. The company also supplies reduced and…
Next-generation viral vectors engineered for safer gene therapy delivery
Sandbox Bioscience is a biotechnology company developing next-generation viral delivery vectors for gene therapy. Founded by a team of virologists with extensive experience in gene therapy delivery systems and platform development, the company is engineering vectors designed to improve on existing market solutions…
Phosphoproteomics platform for kinase activity profiling and precision oncology
Kinomica is a UK precision medicine company developing phosphoproteomics technology for drug discovery and companion diagnostics. Its platform combines LC-MS/MS mass spectrometry with proprietary bioinformatics to measure kinase activity directly from patient samples, enabling drug target identification, monitoring of…
Clinical-stage developer of oncolytic immunotherapies for cancer treatment
Replimune is the UK research and development site of Replimune Group, a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its platform uses genetically engineered herpes simplex viruses to selectively replicate within and destroy tumour cells, releasing tumour antigens and…
Global medical technology company specialising in chronic condition management
Convatec is a global medical products and technologies company focused on chronic condition management. The group develops and manufactures advanced wound care dressings, ostomy care, continence care and infusion care products, including hydrofiber-based, antimicrobial and tissue-derived biomaterial wound dressings…
At-home hormone and fertility diagnostics for women
Hertility Health is a UK digital health and diagnostics company providing at-home hormone and fertility testing for women. Its core product is a CE-marked, MHRA-registered blood test kit that analyses reproductive hormone profiles and screens for conditions including PCOS, endometriosis, and premature ovarian…
Engineered bacterial nanosyringes for intracellular protein delivery
NanoSyrinx is a discovery-stage biotechnology company developing a platform for targeted intracellular delivery of protein and peptide therapeutics. Based on naturally occurring bacterial nanomachines, the company's technology is engineered to deliver biological payloads directly to the cytosol of targeted cells…
AI platform integrating biology, chemistry and automation for drug discovery
Recursion is a clinical-stage biotechnology company using AI and robotic wet-lab automation to industrialise small molecule drug discovery. Its platform integrates phenomics, transcriptomics, proteomics and patient data to identify and optimise drug candidates at scale. Following its acquisition of Oxford-based…
Gene therapy immune regulators for infection, cancer and autoimmunity
Virothera develops gene therapies intended to regulate immune responses in persistent diseases. Its approach draws on human versions of immune-modifying proteins that viruses have evolved to influence immune cells. The company aims to use these proteins to create targeted treatments with potential advantages over some…
Clinical-stage oncology biopharma developing the bispecific antibody ivonescimab
Summit Therapeutics is a clinical-stage oncology company with UK research operations originating from VASTox, a University of Oxford spin-out. The company's lead candidate, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF, in-licensed from Akeso and now in multiple global Phase III trials across non-small…
Biologic therapy for osteoarthritis pain
Levicept is a clinical-stage biotechnology company developing a once-monthly biologic treatment for osteoarthritis pain. Its receptor fusion protein is designed to rebalance neurotrophin signalling in affected joints, potentially providing a non-opioid treatment option. The company has completed a Phase II study…
Single-cell genomics and AI platform for autoimmune and fibrotic disease
Ensocell is a Cambridge-based biotechnology company developing precision biologics for autoimmune, inflammatory, and fibrotic diseases. Its platform integrates single-cell and spatial genomics with AI-based computational tools and advanced cell models to identify novel disease intervention points and design targeted…
Mechanobiology platform for target discovery and validation
Mechanome Bio is a Cambridge-based company developing a mechano-transcriptomics platform for biomarker and drug target discovery. The platform combines spatial multi-omics data from human tissue samples with mechanical tissue profiling and in silico tissue modelling to identify targets linked to changes in tissue…
Reprogrammed stem cell therapies for vascular disease and chronic wounds
ReproGo is a Belfast-based regenerative medicine company developing Advanced Therapy Medicinal Products through direct cell reprogramming of adult cells into vascular lineages. The company's manufacturing approach produces stem cell-derived vascular cells and organoids through a xeno-free, low-dose process designed…
Computationally designed broadly protective vaccines against pandemic viruses
DIOSynVax is a clinical-stage biotechnology company developing broadly protective vaccines using a computational antigen design platform. The company's technology applies protein structure modelling and immune optimisation to engineer synthetic vaccine antigen payloads targeting conserved regions of viruses, enabling…
AI-enabled personalised dosing for drug-digital combination therapies
Closed Loop Medicine develops combination products integrating pharmaceutical therapies with AI-powered digital companions to personalise drug dosing for chronic conditions. Its platform applies pharmacometric modelling and patient response data to optimise treatment regimens. The pipeline includes co-packaged drug…
Genome-editing platform mapping cancer drug resistance and druggable vulnerabilities
BASE Rx is a Wellcome Sanger Institute spin-out applying genome-editing and DNA sequencing technologies to cancer drug discovery. The company maps single-base genetic variants to identify druggable vulnerabilities in cancer genes and predict the DNA changes that drive resistance to cancer therapies. BASE Rx aims to…